Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Subscribe To Our Newsletter & Stay Updated